Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Nephros (NEPH) Acquisitions (2019)

Nephros has reported Acquisitions over the past 1 years, most recently at $137000.0 for Q1 2019.

Quarterly results put Acquisitions at $137000.0 for Q1 2019, changed N/A from a year ago — trailing twelve months through Dec 2019 was $137000.0 (changed N/A YoY), and the annual figure for FY2021 was $49000.0, changed.
Acquisitions for Q1 2019 was $137000.0 at Nephros.
Over the last five years, Acquisitions for NEPH hit a ceiling of $137000.0 in Q1 2019 and a floor of $137000.0 in Q1 2019.